Table 2 Approval status for azacitidine and decitabine in MDS and AML
From: A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
Azacitidine (Vidaza) | Decitabine (Dacogen) | |||
|---|---|---|---|---|
MDS | AML | MDS | AML | |
USA (FDA) | All subtypes | AML 20–30 % blasts (formerly RAEB-t) | All subtypes | AML <30 % blasts (formerly RAEB-t) |
Dose | 75 mg/m2 s.c. days 1–7 q28 | 75 mg/m2 s.c. days 1–7 q28 | 15 mg/m2 i.v. 3× daily days 1–3 q42 or 20 mg/m2 i.v. days 1–5 q28 | 15 mg/m2 i.v. 3× daily days 1–3 q42 or 20 mg/m2 i.v. days 1–5 q28 |
Europe (EMA) | INT2/high-risk MDS according to IPSS, CMML 10–29 % blasts, not eligible for allogeneic SCT | AML ≥65 years regardless of blast counts, not eligible for allogeneic SCT | Not approved | AML ≥65 years not candidates for standard induction chemotherapy |
Dose | 75 mg/m2 s.c. days 1–7 q28 | 75 mg/m2 s.c. days 1–7 q28 | n/a | 20 mg/m2 i.v. days 1–5 q28 |